EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions

Pansakon Wattanachai, Warayuwadee Amornpinyo, Parinya Konyoung, Danklai Purimart, Usanee Khunarkornsiri, Oranuch Pattanacheewapull, Wichittra Tassaneeyakul, Nontaya Nakkam

Frontiers in Pharmacology · 19.09.2023 · 14

DOI: 10.3389/fphar.2023.1248386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.09.2023. Verfasst von Pansakon Wattanachai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Systems Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Beta-lactam antibiotics are one of the most common causes of antibiotics-related severe cutaneous adverse reactions (SCARs) including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reactions with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Recent evidence demonstrated that the human leukocyte antigen ( HLA ) polymorphisms play important roles in the development of drug-related SCARs. This study aimed to extensively characterize the associations between HLA genetic polymorphisms and several phenotypes of SCARs related to beta-lactam antibiotics.

Methods

Thirty-one Thai patients with beta-lactam antibiotics-related SCARs were enrolled in the study. A total of 183 unrelated native Thai subjects without any evidence of drug allergy were recruited as the control group. Genotyping of HLA class I and class II alleles was performed.

Results

Six HLA alleles including HLA-A*01:01 , HLA-B*50:01 , HLA-C*06:02 , HLA-DRB1*15:01 , HLA-DQA1*03:01 , and HLA-DQB1*03:02 , were significantly associated with beta-lactam antibiotics-related SCARs. The highest risk of SCARs was observed in patients with the HLA-B*50:01 allele (OR = 12.6, 95% CI = 1.1–142.9, p = 0.042), followed by the HLA-DQB1*03:02 allele (OR = 5.8, 95% CI = 1.5–22.0, p = 0.012) and the HLA-C*06:02 allele (OR = 5.7, 95% CI = 1.6–19.9, p = 0.011). According to the phenotypes of SCARs related to beta-lactam antibiotics, the higher risk of SJS/TEN was observed in patients with HLA-A*03:02 , HLA-B*46:02 (OR = 17.5, 95% CI = 1.5–201.6, p = 0.033), HLA-A*02:06 , HLA-B*57:01 (OR = 9.5, 95% CI = 1.3–71.5, p = 0.028), HLA-DQB1*03:02 (OR = 7.5, 95% CI = 1.8–30.9, p = 0.008), or HLA-C*06:02 (OR = 4.9, 95% CI = 1.1–21.4, p = 0.008). While eight HLA alleles including HLA-A*02:05 , HLA-A*02:11 , HLA-B*37:01 , HLA-B*38:01 , HLA-B*50:01 , HLA-C*06:02 , HLA-C*03:09 , and HLA-DRB1*15:01 were associated with AGEP, the highest risk of AGEP was observed in patients with the HLA-B*50:01 allele (OR = 60.7, 95% CI = 4.8–765.00, p = 0.005). Among the four HLA alleles associated with DRESS including HLA-C*04:06 , HLA-DRB1*04:05 , HLA-DRB1*11:01 , and HLA-DQB1*04:01 , the HLA-C*04:06 allele had the highest risk of beta-lactam antibiotics-related DRESS (OR = 60.0, 95% CI = 3.0–1202.1, p = 0.043). However, these associations did not achieve statistical significance after Bonferroni’s correction. Apart from the HLA risk alleles, the HLA-A*02:07 allele appeared to be a protective factor against beta-lactam antibiotic-related SCARs (OR = 0.1, 95% CI = 0.0–0.5, p = 3.7 × 10 −4 , Pc = 0.012).

Conclusion

This study demonstrated the candidate HLA alleles that are significantly associated with several phenotypes of beta-lactam antibiotics-related SCARs. However, whether the HLA alleles observed in this study can be used as valid genetic markers for SCARs related to beta-lactam antibiotics needs to be further explored in other ethnicities and larger cohort studies.

Schlagwörter

Stichwörter der Autor:innen

Human Leukocyte AntigenStevens–Johnson syndrome/toxic epidermal necrolysisacute generalized exanthematous pustulosisbeta-lactam antibioticsdrug reactions with eosinophilia and systemic symptomssevere cutaneous adverse reactions

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital, Khon Kaen, Thailand.
  • Pharmacy Unit, Udon Thani Hospital, Udon Thani, Thailand.
  • Pharmacy Department, Khon Kaen Hospital, Khon Kaen, Thailand.

Förderung

  • Health Systems Research Institute

Zitieren

APA

Wattanachai, P., Amornpinyo, W., Konyoung, P., Purimart, D., Khunarkornsiri, U., Pattanacheewapull, O., Tassaneeyakul, W., & Nakkam, N. (2023). Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1248386

Vancouver

Wattanachai P, Amornpinyo W, Konyoung P, Purimart D, Khunarkornsiri U, Pattanacheewapull O, et al. Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1248386

BibTeX
@article{Wattanachai2023,
  author = {Wattanachai, Pansakon and Amornpinyo, Warayuwadee and Konyoung, Parinya and Purimart, Danklai and Khunarkornsiri, Usanee and Pattanacheewapull, Oranuch and Tassaneeyakul, Wichittra and Nakkam, Nontaya},
  title = {Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1248386}
}
Kostenlos starten →